Treating Lysosomal Storage Disease Symptoms with Quinuclidine Compounds

This patent describes methods for using specific quinuclidine compounds, sometimes with enzyme replacement therapy, to treat symptoms like pain and skin issues in patients with lysosomal storage diseases such as Fabry disease.

What it covers

This patent describes ways to treat or prevent specific symptoms and disorders linked to lysosomal storage diseases. It focuses on using 'quinuclidine compounds of formula (I)' for this purpose. The treatment can optionally be combined with enzyme replacement therapy. Examples of symptoms it aims to treat include pain, like abdominal pain, and skin problems such as angiokeratoma. The methods are intended for patients with diseases like Fabry disease.

What it doesn't cover

• —Does not cover treatments using compounds other than quinuclidine compounds of formula (I).
• —Does not cover treatments for diseases that are not classified as lysosomal storage diseases.
• —Does not cover treatments for symptoms unrelated to pain or dermatological disorders in these diseases.
• —Does not cover treatments for lysosomal storage diseases that do not involve either quinuclidine compounds or enzyme replacement therapy.

The clever bit

The novelty lies in identifying a specific class of chemical compounds, 'quinuclidine compounds of formula (I)', for treating particular symptoms of lysosomal storage diseases. This suggests a targeted approach to address specific manifestations like pain and skin issues, potentially offering a new therapeutic pathway.

Why it matters

Lysosomal storage diseases are a group of rare, inherited metabolic disorders that can cause severe health problems, including chronic pain and organ damage. New therapeutic approaches, especially those targeting specific symptoms, can significantly improve the quality of life for affected patients. Fabry disease, for example, is a serious condition where effective symptom management is crucial.

Real-world examples

• 1.Pharmaceutical treatments for rare genetic disorders
• 2.Drug therapies for Fabry disease
• 3.Enzyme replacement therapy adjuncts